HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

asperolide A

from the marine alga-derived endophytic fungus Aspergillus wentii EN-48; structure in first source

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Terpenes: 1461
    - Diterpenes: 1470
      - asperolide A: 4

Experts

1.	Huang, Caiguo: 2 articles (11/2020 - 01/2013)
2.	Huang, Hao: 1 article (11/2020)
3.	Jiang, Wenli: 1 article (11/2020)
4.	Jiao, Binghua: 1 article (11/2020)
5.	Rixiati, Youlutuziayi: 1 article (11/2020)
6.	Shi, YiJun: 1 article (11/2020)
7.	Chen, Ruohua: 1 article (01/2013)
8.	Lv, Cuiting: 1 article (01/2013)
9.	Sun, Haofen: 1 article (01/2013)
10.	Sun, Wenxia: 1 article (01/2013)

Related Diseases

1.	Neoplasms (Cancer) 01/29/2013 - "Overall, these findings provide potential effectiveness and a theoretical basis for the therapeutic use of asperolide A in the treatment of malignancies." 01/29/2013 - "An in vivo study with asperolide A illustrated a marked inhibition of tumor growth, and little toxcity compared to Cisplatin therapy. "
2.	Carcinoma (Carcinomatosis) 01/29/2013 - "This study indicates that asperolide A-induced G2/M arrest in human NCI-H460 lung carcinoma cells relys on the participation of the Ras/Raf/MEK/ERK signaling pathway in p53-p21 stabilization. " 01/29/2013 - "Here we first demonstrate that asperolide A, a very recently reported marine-derived tetranorditerpenoid, leads to the inhibition of NCI-H460 lung carcinoma cell proliferation by G2/M arrest with the activation of the Ras/Raf/MEK/ERK signaling and p53-dependent p21 pathway. " 01/29/2013 - "Asperolide A, a marine-derived tetranorditerpenoid, induces G2/M arrest in human NCI-H460 lung carcinoma cells, is mediated by p53-p21 stabilization and modulated by Ras/Raf/MEK/ERK signaling pathway."
3.	Breast Neoplasms (Breast Cancer) 11/01/2020 - "Asperolide A prevents bone metastatic breast cancer via the PI3K/AKT/mTOR/c-Fos/NFATc1 signaling pathway." 09/01/2022 - "Regarding patients with breast cancer, we found the following: Asperolide A could be another curative drug; targeting transforming growth factor-beta (TGFβ) and bone morphogenetic protein (BMP) signaling pathways, along with osteoclast activity, could be a favorable therapeutic approach in the preclusion of osteolytic bone destruction; TRAF6 inhibitors such as 6877002 appear promising; aiming the BMP4-SMAD7 signaling axis is an innovative therapeutic approach; there is favorable proof for the plausible therapeutic utilization of bone aiming immunostimulatory MOF (BT-isMOF) nanoparticles, and inhibition of IL4R and macrophages could have therapeutic benefits. "
4.	Osteolysis 11/01/2020 - "We examined the effect of Asperolide A (AA), a marine-derived agent, on osteolysis and RANKL-induced phosphoinositide 3-kinase (PI3K)/AKT/mTOR/c-FOS/nuclear factor-activated T cell 1 (NFATc1) pathway activation, F-actin ring formation, and reactive oxygen species (ROS) generation in vitro. "
5.	Hepatocellular Carcinoma (Hepatoma) 03/01/2023 - "Asperolide A induces apoptosis and cell cycle arrest of human hepatoma cells with p53-Y220C mutant through p38 mediating phosphorylation of p53 (S33)."

Related Drugs and Biologics

1.	Mitogen-Activated Protein Kinase Kinases (MEKs)
2.	Cisplatin (Platino)
3.	TNF Receptor-Associated Factor 6 (TRAF6)
4.	Therapeutic Uses
5.	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)
6.	Reactive Oxygen Species (Oxygen Radicals)
7.	Transforming Growth Factor beta (TGF-beta)
8.	Proteins (Proteins, Gene)
9.	Phosphatidylinositols (Phosphatidylinositol)
10.	Actins (F Actin)

Related Therapies and Procedures

1.	Therapeutics